Outset Medical Inc. ($OM) reported fourth-quarter 2025 results with revenue of $28.9 million, down 2.0% year-over-year, beating the consensus revenue estimate of $27.4 million.
The company showed margin improvement at the gross-profit level while overall profitability deteriorated. Gross profit grew year-over-year, but operating and net losses increased, and diluted earnings per share missed expectations.
In summary, Outset Medical ($OM) delivered a modest revenue beat with improving gross margins, but the quarter was marked by wider operating and net losses, a larger-than-expected per-share loss, and a material decline in cash balances and operating cash flow.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Outset Medical Inc. Insider Trading Activity
Outset Medical Inc. insiders have traded $OM stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 5 sales selling 17,529 shares for an estimated $94,613.
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 5 sales selling 11,489 shares for an estimated $61,273.
- MARC NASH (EVP Operations R&D & Service) has made 0 purchases and 5 sales selling 6,953 shares for an estimated $37,127.
- KAREN DREXLER sold 1,548 shares for an estimated $6,764
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Outset Medical Inc. Hedge Fund Activity
We have seen 52 institutional investors add shares of Outset Medical Inc. stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,621,137 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $22,890,454
- DURABLE CAPITAL PARTNERS LP removed 633,420 shares (-38.2%) from their portfolio in Q3 2025, for an estimated $8,943,890
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 631,663 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,343,469
- BML CAPITAL MANAGEMENT, LLC added 543,180 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,015,197
- PURA VIDA INVESTMENTS, LLC removed 424,120 shares (-98.8%) from their portfolio in Q3 2025, for an estimated $5,988,574
- MORGAN STANLEY added 311,805 shares (+256.9%) to their portfolio in Q3 2025, for an estimated $4,402,686
- BLACKROCK, INC. added 265,065 shares (+26.9%) to their portfolio in Q3 2025, for an estimated $3,742,717
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Outset Medical Inc. Analyst Ratings
Wall Street analysts have issued reports on $OM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/16/2025
To track analyst ratings and price targets for Outset Medical Inc., check out Quiver Quantitative's $OM forecast page.
Outset Medical Inc. Price Targets
Multiple analysts have issued price targets for $OM recently. We have seen 3 analysts offer price targets for $OM in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Rick Wise from Stifel set a target price of $8.0 on 01/07/2026
- Marie Thibault from BTIG set a target price of $17.0 on 12/16/2025
- Shagun Singh from RBC Capital set a target price of $17.0 on 11/11/2025
